Hormone Therapy News

Swedish women assigned oral contraceptives reported reduced general well-being, but similar burden of depressive symptoms, compared with women assigned placebo, according to findings published in Fertility and Sterility.

In adolescents transitioning from male to female, estrogen therapy for at least 1 year was effective and safe for inducing puberty, study data show.

In female-to-male transgender patients, subcutaneous testosterone therapy was safe and effective and was the preferred route of therapy in patients previously receiving intramuscular injections, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

WASHINGTON — Hormone therapy was associated with lower coronary artery calcium scores and, after adjustment, with lower all-cause mortality in postmenopausal women, according to findings presented at the American College of Cardiology Scientific Session.

ORLANDO, Fla. — An investigational combination of 17beta-estradiol and progesterone appears to be safe and effective for reducing hot flash frequency and severity in menopausal women, according to results of the REPLENISH trial reported here.

ORLANDO, Fla. — A twice-monthly investigational therapy for children with growth hormone deficiency was effective for increasing growth rates when the dose was increased to 3.5 mg/kg twice per month, according to study findings presented here.

ORLANDO, Fla. — In healthy, middle-aged and older men, treatment with the natural fetal estrogen estetrol led to a decrease in both total and free testosterone levels with only mild side effects, suggesting the therapy may be suitable in prostate cancer treatment, according to study findings presented here.

ORLANDO, Fla. — Almost one-quarter of transgender adults surveyed in Toronto reported valuing their fertility, and many expressed willingness to delay or temporarily halt hormonal transition to regain that fertility, according to a presenter at the Endocrine Society Annual Meeting.

ORLANDO, Fla. — Breast development in transgender women treated with cross-sex hormonal therapy occurs primarily in the first 6 months of administration and stabilizes with no increase during the last 6 months, according to research presented here.

ORLANDO, Fla. — The profile of metabolic disease risk among adolescents transitioning from female to male and adolescents with polycystic ovary syndrome may not be similar despite elevated serum testosterone concentrations in both groups.